Skip to content

Mind-body Medicine for Patients With Malignant Hematological Diseases

Mind-body Medicine as a Supportive Strategy for Patients With Malignant Hematological Diseases: a Randomized Controlled Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03735992
Enrollment
94
Registered
2018-11-08
Start date
2017-09-06
Completion date
2026-12-31
Last updated
2026-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematologic Neoplasms

Keywords

Hematologic Neoplasms, Supportive Therapy, Fatigue, Mind-body medicine, Complementary and alternative medicine

Brief summary

This randomized controlled trial aims to investigate the effectiveness of a mind-body group program as a supprtivemanagement strategy for fatigue in patients with malignant hematological diseases.

Interventions

BEHAVIORALMind-body medicine group program

The group program is mainly based on MBSR. It further integrates elements of the mind-body medicine cancer program of the Benson-Henry Mind/Body Medical Institute at Harvard Medical School which is rooted in psychoneuroendocrinology and focuses on relaxation techniques, exercise, cognitive restructuring, diet, and social support. In addition, naturopathic methods of selfregulation and self-care are incorporated.

Sponsors

Universität Duisburg-Essen
Lead SponsorOTHER
Robert Bosch Medical Center
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with malignant hematological diseases in complete remission after primary chemotherapy and/or radiation * Physical and mental ability to attent 8 of 11 group units

Exclusion criteria

* Chemotherapy, radiation, or rehabilitation programm during the study period * Pregnancy * Participation in other studies with behavioral interventions during the study period

Design outcomes

Primary

MeasureTime frameDescription
General Fatigueweek 12Multidimensional Fatigue Inventory (MFI) - General Fatigue Subscale

Secondary

MeasureTime frameDescription
General Fatigueweek 24Multidimensional Fatigue Inventory (MFI) - General Fatigue Subscale
Physical Fatigueweek 12Multidimensional Fatigue Inventory (MFI) - Physical Fatigue Subscale
Reduced Activityweek 12Multidimensional Fatigue Inventory (MFI) - Reduced Activity Subscale
Reduced Motivationweek 12Multidimensional Fatigue Inventory (MFI) - Reduced Motivation Subscale
Mental Fatigueweek 12Multidimensional Fatigue Inventory (MFI) - Mental Fatigue Subscale
Qaulity of lifeweek 12Functional Assessment of Cancer Therapy - General (FACT-G)
Depressionweek 12Hospital Anxiety and Depression Scale - Depression subscale (HADS-D)
Anxietyweek 12Hospital Anxiety and Depression Scale - Anxiety Subscale (HADS-A)
Stressweek 12Perceived Stress Scale (PSS)
Sleepweek 12Pittsburgh Sleep Quality Index (PSQI)
Physical activityweek 12Motion sensor (activPAL3, Pal Technologies, Glasgow, Schottland)
Fatigabilityweek 1230-Second Chair Stand Test
Adverse Eventsweek 12Number of patients with adverse events

Countries

Germany

Contacts

CONTACTHolger Cramer, PhD
holger.cramer@med.uni-tuebingen.de+4971181017860
CONTACTHeidemarie Haller, PhD
heidemarie.haller@uk-essen.de+4920172377382
STUDY_DIRECTORGustav Dobos, Prof. MD

Center for Integrative Medicine and Health, University Hospital Essen, University of Duisburg-Essen

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 16, 2026